The Emergence of Biologics
While small molecules dominate the Acute Coronary Syndrome (ACS) Market, biologics are emerging as a promising area of innovation. Biologics, such as monoclonal antibodies, are large-molecule drugs that can be highly targeted and specific in their action. They are being developed to address specific inflammatory and thrombotic pathways that contribute to ACS.
For instance, pipeline drugs like Novo Nordisk's Ziltivekimab, a monoclonal antibody, are targeting inflammation in cardiovascular disease, which is a major driver of plaque instability. The development of such targeted therapies holds the potential to improve patient outcomes, particularly for those with complex or high-risk conditions. This move towards precision medicine with biologics represents a key technological shift in the Acute Coronary Syndrome Market.